Shopping Cart 0
Cart Subtotal
USD 0

Akorn Inc (AKRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Akorn Inc (Akorn) develops, manufactures, and commercializes generic and branded prescription pharmaceuticals and branded and over-the-counter consumer health products and animal health pharmaceuticals. The company offers its products in both sterile and non-sterile dosage forms including oral liquids, otics, ophthalmics, injectables, topicals, inhalants, and nasal sprays. It also offers contract manufacturing services. Akorn caters to physicians, surgery centers, clinics, optometrists, hospitals, long-term care, wholesalers, retail pharmacies, group purchasing organizations and other pharmaceutical companies. The company has manufacturing facilities in India and the US. It operates in the US, Canada, Mauritius, Luxembourg, Switzerland and India. Akorn is headquartered in Lake Forest, Illinois, the US.

Akorn Inc (AKRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10

Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Akorn Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 13

Oak Pharma Acquires Tafluprost Business from Merck 14

Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 15

Akorn Acquires Betimol, Opthalmic Drug, From Santen 16

Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 17

Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 18

Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 19

Partnerships 20

Hi-Tech Pharma Forms Joint Venture with Shanghai Yongyi Biotech 20

Knight Therapeutics Enters into Distribution Agreement with Akorn 21

Licensing Agreements 22

Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 22

Santen Pharma Enters into Licensing Agreement with Oak Pharma 23

Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 24

Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 25

Asset Transactions 26

Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 26

Acquisition 28

Hi-Tech Pharma Acquires FormuTech Nutrition 28

Hi-Tech Pharma to Acquire Advanced Pharma 29

Akorn Acquires Excelvision for USD25.9 Million 30

Akorn Acquires VersaPharm from Tailwind Capital Partners 31

Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 33

Akorn Completes Acquisition Of Hi-Tech Pharmacal For USD 640 Million 34

Akorn Acquires Inspire Pharma From Merck For USD 53 Million 36

Serum Institute Plans To Sell Its Stake In Akorn 38

Akorn Inc-Key Competitors 40

Akorn Inc-Key Employees 41

Akorn Inc-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Joint Venture 43

Recent Developments 44

Financial Announcements 44

Nov 06, 2018: Akorn provides third quarter 2018 results 44

Mar 01, 2017: Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance 45

Legal and Regulatory 47

Oct 01, 2018: Akorn comments on Delaware Chancery Court Ruling 47

Feb 26, 2018: Akorn Issues Statement on Investigation 48

Feb 09, 2018: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals Investors 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Akorn Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akorn Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10

Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 13

Oak Pharma Acquires Tafluprost Business from Merck 14

Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 15

Akorn Acquires Betimol, Opthalmic Drug, From Santen 16

Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 17

Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 18

Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 19

Hi-Tech Pharma Forms Joint Venture with Shanghai Yongyi Biotech 20

Knight Therapeutics Enters into Distribution Agreement with Akorn 21

Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 22

Santen Pharma Enters into Licensing Agreement with Oak Pharma 23

Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 24

Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 25

Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 26

Hi-Tech Pharma Acquires FormuTech Nutrition 28

Hi-Tech Pharma to Acquire Advanced Pharma 29

Akorn Acquires Excelvision for USD25.9 Million 30

Akorn Acquires VersaPharm from Tailwind Capital Partners 31

Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 33

Akorn Completes Acquisition Of Hi-Tech Pharmacal For USD 640 Million 34

Akorn Acquires Inspire Pharma From Merck For USD 53 Million 36

Serum Institute Plans To Sell Its Stake In Akorn 38

Akorn Inc, Key Competitors 40

Akorn Inc, Key Employees 41

Akorn Inc, Subsidiaries 42

Akorn Inc, Joint Venture 43

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Akorn Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Akorn Inc (Akorn) develops, manufactures, and commercializes generic and branded prescription pharmaceuticals and branded and over-the-counter consumer health products and animal health pharmaceuticals. The company offers its products in both sterile and non-sterile dosage forms including oral liquids, otics, ophthalmics, injectables, topicals, inhalants, and nasal sprays. It also offers contract manufacturing services. Akorn caters to physicians, surgery centers, clinics, optometrists, hospitals, long-term care, wholesalers, retail pharmacies, group purchasing organizations and other pharmaceutical companies. The company has manufacturing facilities in India and the US. It operates in the US, Canada, Mauritius, Luxembourg, Switzerland and India. Akorn is headquartered in Lake Forest, Illinois, the US.

Akorn Inc (AKRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10

Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Akorn Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 13

Oak Pharma Acquires Tafluprost Business from Merck 14

Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 15

Akorn Acquires Betimol, Opthalmic Drug, From Santen 16

Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 17

Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 18

Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 19

Partnerships 20

Hi-Tech Pharma Forms Joint Venture with Shanghai Yongyi Biotech 20

Knight Therapeutics Enters into Distribution Agreement with Akorn 21

Licensing Agreements 22

Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 22

Santen Pharma Enters into Licensing Agreement with Oak Pharma 23

Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 24

Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 25

Asset Transactions 26

Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 26

Acquisition 28

Hi-Tech Pharma Acquires FormuTech Nutrition 28

Hi-Tech Pharma to Acquire Advanced Pharma 29

Akorn Acquires Excelvision for USD25.9 Million 30

Akorn Acquires VersaPharm from Tailwind Capital Partners 31

Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 33

Akorn Completes Acquisition Of Hi-Tech Pharmacal For USD 640 Million 34

Akorn Acquires Inspire Pharma From Merck For USD 53 Million 36

Serum Institute Plans To Sell Its Stake In Akorn 38

Akorn Inc-Key Competitors 40

Akorn Inc-Key Employees 41

Akorn Inc-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Joint Venture 43

Recent Developments 44

Financial Announcements 44

Nov 06, 2018: Akorn provides third quarter 2018 results 44

Mar 01, 2017: Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance 45

Legal and Regulatory 47

Oct 01, 2018: Akorn comments on Delaware Chancery Court Ruling 47

Feb 26, 2018: Akorn Issues Statement on Investigation 48

Feb 09, 2018: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals Investors 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Akorn Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akorn Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10

Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 13

Oak Pharma Acquires Tafluprost Business from Merck 14

Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 15

Akorn Acquires Betimol, Opthalmic Drug, From Santen 16

Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 17

Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 18

Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 19

Hi-Tech Pharma Forms Joint Venture with Shanghai Yongyi Biotech 20

Knight Therapeutics Enters into Distribution Agreement with Akorn 21

Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 22

Santen Pharma Enters into Licensing Agreement with Oak Pharma 23

Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 24

Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 25

Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 26

Hi-Tech Pharma Acquires FormuTech Nutrition 28

Hi-Tech Pharma to Acquire Advanced Pharma 29

Akorn Acquires Excelvision for USD25.9 Million 30

Akorn Acquires VersaPharm from Tailwind Capital Partners 31

Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 33

Akorn Completes Acquisition Of Hi-Tech Pharmacal For USD 640 Million 34

Akorn Acquires Inspire Pharma From Merck For USD 53 Million 36

Serum Institute Plans To Sell Its Stake In Akorn 38

Akorn Inc, Key Competitors 40

Akorn Inc, Key Employees 41

Akorn Inc, Subsidiaries 42

Akorn Inc, Joint Venture 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Akorn Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.